Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorasidenib in IDH-mutant Grade 2 Glioma (INDIGO)
NCT04164901Phase 3Active, not recruiting
- Sponsor
- Servier
- Start
- Jan 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of vorasidenib in glioma, sponsored by Servier. Started Jan 2020; status: active, not recruiting.
02
Drugs
vorasidenib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT04164901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04164901.